Trade less - Make more Win big - Lose small Quality over Quantity Do not over trade and only strike when it’s hot Discipline decides your destiny 🌕🚨🔮💸 That’s the motto

$SNAL watch for dips, it’s setting up nicely. Break and hold $2,5 and $2.7 for $3+

I had a guy who went to college for finance and stock stuff tell me recently “timing is a fools game” Tell me you can’t read a chart without telling me you can’t read a chart I’ll never understand that saying “timing is a fools game” I’ve made majority of my money from timing stuff. Timing is everything imo

$GIS $LULU $HPQ $CSGP $LMT $KHC $ADBE $INTU $AMTM $ALKT $PG $TTD $HD Not caring what the market is doing.

The amount of bottom snipes and banger large caps and mid caps I gave you in the last 2 weeks is insane. $AMTM $CSGP $INTU $ALKT $HD $KHC $PG $ISRG $CHTR $UPS

$AMTM here we go

$GIS strong day already

I’ve been adding $ISRG since the mid $300s This is what they do in simple terms ISRG makes advanced surgical robots that help doctors perform operations with smaller cuts, greater precision, and potentially faster patient recovery. Its da Vinci system allows surgeons to control tiny instruments using a specialized console, making complex surgeries easier to perform. The future is moving toward robotic assisted surgery because technology can help improve precision, reduce invasiveness, and expand the types of procedures doctors can perform. As more hospitals adopt these systems and more surgeries use robotic assistance, ISRG can generate recurring revenue by selling instruments, supplies, and servicing its equipment. It’s a way to invest in the long term growth of medical technology as surgery becomes increasingly advanced.

$HD $MCD $LOW etc Consumer stocks getting pre loaded for Santa rally

$SNAL “Watch for dips” Here’s your dip. I’m accumulating 1.90 to 2.15 area slowly and swinging

$500 on deck $ISRG

$BMRN Meets my beat down chart criteria. $BMRN is positioning itself at the intersection of biotechnology and AI- powered medicine. Its partnership with Profluent brings AI designed enzyme therapies into the picture, potentially helping BioMarin develop innovative treatments for rare genetic diseases faster and more efficiently. With its established rare-disease expertise and growing AI capabilities, BMRN has an exciting long-term opportunity to improve its drug pipeline, unlock new therapies, and create additional shareholder value as AI transforms drug discovery.

break and hold $13.33 and this can start getting squeezy. $14 / $14.5 / 15.00 / 17.00

$ALKT wants to fill the gap on the daily

$SNAL at the same spot on the chart before it ran 500% $7 intrinsic value Crypto and Ai ties

$ENPH sentiment could turn fast on this name. $ENPH A beaten down solar technology leader with a potential recovery ahead. Enphase makes microinverters, home batteries, and energy management systems, positioning it to benefit as homeowners look for greater energy independence and lower electricity bills. The recovery thesis centers on a rebound in U.S.

$AAON $90 intrinsic value, under the 200MA weekly $AAON 🚀 A major AI data center cooling play. AAON manufactures advanced HVAC and thermal management systems, with its BASX division benefiting from surging demand for data center cooling and liquid-cooling infrastructure. Q2 2026 revenue more than doubled year over year to a record $627M, while its backlog remained near $2B. Management raised its full-year sales growth outlook to 55%–60%, highlighting the strength of demand. As AI infrastructure expands, cooling becomes increasingly critical, and AAON is investing in manufacturing capacity to capture more of this opportunity. If production ramps smoothly and margins improve as new facilities become more efficient, earnings and cash flow could accelerate further. Explosive growth, massive backlog, and direct exposure to the AI infrastructure boom make $AAON a compelling company to watch.

$CCOI beat down, $29 intrinsic value $CCOI Cogent Communications operates a global internet backbone, providing high- speed internet, IP transit, and network connectivity to businesses and other carriers. The bullish recovery case centers on improving network revenue, growing internet traffic, expanding margins, and reducing its heavy debt load. In Q2 2026, adjusted EBITDA rose 1.3% sequentially, on-net revenue grew 6.2% year over year, and network traffic increased 16% year over year. If revenue stabilizes, profitability improves, and debt refinancing concerns ease, investor sentiment could turn and drive a meaningful recovery toward $29. A beaten down telecom infrastructure play with improving operating metrics and significant recovery potential.

$GIS $50 intrinsic value thesis. General Mills could be an attractive value recovery play as investors price in weak consumer spending, declining sales, and margin pressure. The turnaround depends on stabilizing sales volumes, winning back consumers through stronger products and competitive pricing, and delivering on its $3 billion cost savings plan through 2030. Management is targeting at least $750 million in savings in fiscal 2027, which could help offset inflation and support earnings. If sales stabilize, profit margins improve, and cash flow remains strong enough to support its dividend and reduce debt, investor sentiment could shift and drive a meaningful recovery from depressed levels. A trusted portfolio of household brands, significant cost cutting potential, and a discounted valuation make $GIS a contrarian recovery candidate.